Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp. has successfully conducted its Annual General Meeting, with a 62.78% turnout of shareholders who unanimously approved all proposed resolutions, including the election of six board directors and the reappointment of PricewaterhouseCoopers LLP as the company’s auditor. Profound continues to innovate in incision-free therapies with its TULSA-PRO and Sonalleve systems, which are designed for customizable tissue ablation and have received multiple regulatory approvals worldwide.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
